Design, synthesis, and biological evaluation of 1-[(2-benzyloxyl/alkoxyl)methyl]-5-halo-6-aryluracils as potent HIV-1 non-nucleoside reverse transcriptase inhibitors with an improved drug resistance profile.
about
Structure-based methods for predicting target mutation-induced drug resistance and rational drug design to overcome the problemHalogen-enriched fragment libraries as chemical probes for harnessing halogen bonding in fragment-based lead discovery.Development and validation of a high performance liquid chromatography method for determination of 6-benzyl-1-benzyloxymethyl-5-iodouracil (W-1), a novel non-nucleoside reverse transcriptase inhibitor and its application to a pharmacokinetic study iThe HEPT Analogue WPR-6 Is Active against a Broad Spectrum of Nonnucleoside Reverse Transcriptase Drug-Resistant HIV-1 Strains of Different Serotypes.Novel HIV-1 non-nucleoside reverse transcriptase inhibitors: a patent review (2011-2014).ANN QSAR workflow for predicting the inhibition of HIV-1 reverse transcriptase by pyridinone non-nucleoside derivatives.A stereo configuration-activity study of 3-iodo-4-(2-methylcyclohexyloxy)-6-phenethylpyridin-2(2H)-ones as potency inhibitors of HIV-1 variants.Docking Field-based QSAR and pharmacophore studies on the substituted pyrimidine derivatives targeting HIV-1 reverse transcriptase.Profile of disposition, tissue distribution and excretion of the novel anti-human immunodeficiency virus (HIV) agent W-1 in rats.Double Variational Binding--(SMILES) Conformational Analysis by Docking Mechanisms for Anti-HIV Pyrimidine Ligands.Synthesis and biological evaluation of novel 2-arylalkylthio-5-iodine-6-substituted-benzyl-pyrimidine-4(3H)-ones as potent HIV-1 non-nucleoside reverse transcriptase inhibitors.Effects of crystalline state and self-nanoemulsifying drug delivery system (SNEDDS) on oral bioavailability of the novel anti-HIV compound 6-benzyl-1-benzyloxymethyl-5-iodouracil in rats.Identification of cytochrome P450s involved in the metabolism of 6-benzyl-1-benzyloxymethyl-5-iodouracil (W-1) using human recombinant enzymes and rat liver microsomes in vitro.
P2860
Q26829549-792F6B4C-B8DB-4861-BA01-281116278679Q35181268-4CF1A769-BCC6-405F-A17F-B5061CB1E679Q35586639-FACBF323-D612-4098-A8C7-3F466119080AQ35859896-A0DB46DE-6CFA-461C-8CD4-51DAACCEBCABQ38260066-03EE3862-4613-464B-803B-01E182D69B21Q38655334-A3EE9BBB-9527-4B17-A2C6-3BB3685305AEQ38811174-EDF38D68-5C25-4A47-971E-3BE5012C1B0BQ40080043-E9E1A28A-6A5C-42C4-AE64-31B41F737C41Q40708931-2EFF3510-CFEF-4EA3-944E-E4B3A83D1594Q41040182-47E31877-2A63-4FD3-877E-CB89694F9C87Q42215254-B2CBB0A5-36D5-42D3-B993-B56DF0CA2EB3Q48608254-590D698A-C05D-4CB4-A40A-AB2A4714934FQ51031739-BC89A04A-39D4-4CAB-948C-79B7B156E6FC
P2860
Design, synthesis, and biological evaluation of 1-[(2-benzyloxyl/alkoxyl)methyl]-5-halo-6-aryluracils as potent HIV-1 non-nucleoside reverse transcriptase inhibitors with an improved drug resistance profile.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Design, synthesis, and biologi ...... roved drug resistance profile.
@ast
Design, synthesis, and biologi ...... roved drug resistance profile.
@en
type
label
Design, synthesis, and biologi ...... roved drug resistance profile.
@ast
Design, synthesis, and biologi ...... roved drug resistance profile.
@en
prefLabel
Design, synthesis, and biologi ...... roved drug resistance profile.
@ast
Design, synthesis, and biologi ...... roved drug resistance profile.
@en
P2093
P2860
P356
P1476
Design, synthesis, and biologi ...... roved drug resistance profile.
@en
P2093
Jianfang Zhang
Liang Zhang
Liangren Zhang
Ruiping Wang
P2860
P304
P356
10.1021/JM201506E
P407
P50
P577
2012-02-17T00:00:00Z